Which glioblastoma patients will respond to immunotherapy?



Which glioblastoma patients will respond to immunotherapy?

Scientists have discovered a new biomarker to identify which patients with brain tumors called glioblastomas — the most common and malignant of primary brain tumors — might benefit from immunotherapy. The treatment could extend survival for an estimated 20% to 30% of patients. Currently, patients with glioblastoma do not receive this life-prolonging treatment because it has not been fully understood which of them could benefit.

Materials provided by Northwestern University. Original written by Marla Paul. Note: Content may be edited for style and length.




Source link aaaaa

Related posts

9th December 2022

Clues found regarding tumor suppressor gene's breast cancer activity

Read more
9th December 2022

New findings on how to avert excessive weight loss from COVID-19

Read more
9th December 2022

P53 could be key to therapies for salivary gland cancer

Read more